Based on our findings of TET2-mediated targeting (Figs. 3 and 4) and TET2 inhibitors’ drug efficacy (Fig. 6) in vitro in SARS-CoV-2-infected hiPSC-CMs and computational molecular docking analysis (Figs. 5 and 7), the identification of TET2-mediated hm5C methylation presents a broad spectrum of main infectious activities and may serve as novel anti-COVID-19 agents against host-infectious therapeutics for RNA-based emergent infectious diseases (Fig. 8). The gene discussed is TET2; the disease is COVID-19.